Stockscreener 앱 받기
280.78
0.36%
-1.01
시간 외 거래:
280.78
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
PRAX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $1201 - GuruFocus
PRAX Reiterated by Needham -- Price Target Maintained at $582 - GuruFocus
Praxis Precision Medicines Slides as Investors Weigh Earlier Trial Miss and Upcoming FDA Decisions - Quiver Quantitative
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines (PRAX) Stock Analysis: Evaluating a Potential 105.72% Upside in CNS Therapies - directorstalkinterviews.com
Remagine Labs Pty Ltd announced that it has received funding from Praxis Precision Medicines, Inc., Monash Investment Holdings, Innovation Victoria Pty Ltd - marketscreener.com
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade) - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Praxis Precision Medicines (PRAX) Q2 2026 Earnings: Narrower Loss Beats Estimates by 23.14%Dividend Cut Risk - careplusvn.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Sixty-six new employees receive stock awards from Praxis. They vest over four years. - stocktitan.net
Praxis Precision Medicines (PRAX) Climbs 1.23% as Shares Press Toward $375.69 ResistanceRounding Top - careplusvn.com
PRAX Stock Price, Quote & News - Syfe
S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead - Barron's
Breakeven On The Horizon For Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Moomoo
PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $575 - Moomoo
Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
PRAX Q2 2026 Earnings: Narrower-Than-Expected Loss of -$2.87 Highlights Cost DisciplineEarnings Volatility Report - careplusvn.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria
Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo
Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia
Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances - simplywall.st
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest? - Yahoo Finance
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800 - Moomoo
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Praxis: Commercial Launch Could Smash Expectations (Video) - Seeking Alpha
3.06%
2.55%
자본화:
|
볼륨(24시간):